Longeveron (LGVN) Operating Expenses (2020 - 2026)
Longeveron (LGVN) posted quarterly Operating Expenses of $5.0 million for Q1 2026, down 7.64% year-over-year from $5.5 million in Q1 2025, and down 10.91% quarter-over-quarter from $5.7 million in Q4 2025.
Longeveron (LGVN) Operating Expenses (2020 - 2026) Analysis & Trends
Longeveron's Operating Expenses history runs 7 years deep, the most recent figure standing at $5.0 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 7.64% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $23.7 million (up 21.76% YoY), while the FY2025 annual figure was $24.1 million, up 30.88% from the prior year.
- Operating Expenses for Q1 2026 stood at $5.0 million, down from $5.7 million in the prior quarter.
- The five-year high for Operating Expenses was $7.4 million in Q3 2025, with the low at $3.6 million in Q1 2022.
- The 5-year median for Operating Expenses is $5.2 million (2023), against an average of $5.1 million.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses sank 33.78% in 2024, then soared 44.2% in 2025.
- Longeveron's Operating Expenses stood at $5.2 million in 2022, then gained by 4.86% to $5.4 million in 2023, then declined by 11.53% to $4.8 million in 2024, then rose by 17.56% to $5.7 million in 2025, then fell by 10.91% to $5.0 million in 2026.
- Business Quant data shows LGVN's Operating Expenses at $5.0 million in Q1 2026, $5.7 million in Q4 2025, and $7.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 6.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.35 Mn |
| Mar 31, 2026 | 5.04 Mn |
| Dec 31, 2025 | 5.66 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 5.54 Mn |
| Mar 31, 2025 | 5.46 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 5.33 Mn |
| Jun 30, 2024 | 3.84 Mn |
| Mar 31, 2024 | 4.42 Mn |
| Dec 31, 2023 | 5.44 Mn |
| Sep 30, 2023 | 5.22 Mn |
| Jun 30, 2023 | 5.81 Mn |
| Mar 31, 2023 | 4.79 Mn |
| Dec 31, 2022 | 5.19 Mn |
| Sep 30, 2022 | 5.28 Mn |
| Jun 30, 2022 | 4.38 Mn |
| Mar 31, 2022 | 3.56 Mn |
| Dec 31, 2021 | 4.10 Mn |
| Sep 30, 2021 | 5.07 Mn |